Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
about
Management of low (favourable)-risk prostate cancerThe development of instruments to measure the work disability assessment behaviour of insurance physiciansTime trends and local variation in primary treatment of localized prostate cancerFifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancerPrevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.Can self-reported disability assessment behaviour of insurance physicians be explained? Applying the ASE modelComparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.Preoperative laboratory testing in patients undergoing elective, low-risk ambulatory surgery.Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.Impact of age at diagnosis on prostate cancer treatment and survivalSurgeon and Facility Variation in the Use of Minimally Invasive Breast Biopsy in Texas.Physician variation in management of low-risk prostate cancer: a population-based cohort studyReimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancerGonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuseNationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project.Variation in the use of intraoperative cholangiography during cholecystectomy.Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancerUsing the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Can prophylactic breast irradiation contribute to cardiac toxicity in patients with prostate cancer receiving androgen suppressing drugs?Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States.Impact of Prostate Cancer Diagnosis on Noncancer Hospitalizations Among Elderly Medicare Beneficiaries With Incident Prostate CancerTypes of chronic conditions combinations and initial cancer treatment among elderly Medicare beneficiaries with localised prostate cancer.Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based StudySurvival following primary androgen deprivation therapy among men with localized prostate cancerDiffusion of surgical innovation among patients with kidney cancer.Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment.Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina.Patient anxiety about prostate cancer independently predicts early initiation of androgen deprivation therapy for biochemical cancer recurrence in older men: a prospective cohort study.Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer.Trends in radical prostatectomy.Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly womenTrends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.Androgen deprivation therapy: evidence-based management of side effects.Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.
P2860
Q26996501-DFDC88E9-D246-419C-A9A7-7854A7A38DBAQ30500028-F2873369-D44B-4D65-9BE3-4FDF69AAA95AQ33710948-183CA835-1FA9-4687-A434-42B4B0AF3AB6Q33877542-A2B4C2F5-2264-444C-A0FB-2FC1144C3B8FQ33926384-0440B184-FC5A-4B09-82D3-0F58FB9C5229Q33965537-CD869612-6844-4D82-A707-49D827578E30Q34288796-6A4C1E86-02A4-4748-BF07-884DDAACDB56Q34292539-7EDE5C7D-E961-4378-8821-FDDBEFEC3514Q34366865-D8B6CF4F-396B-4E38-B1AE-AC7EDC2C5D86Q34679220-0E0FEC70-0CF3-4625-81CD-C73FF9543E39Q35133492-552E46B3-9380-4541-9A29-D8FC8F4BE0F1Q35213290-E7EBA43E-C415-4E97-B35E-3F0432DB21C9Q35441262-36E8318B-F040-424C-8F2E-B3248CE59521Q35602510-F6F9299C-C701-4459-BE11-C98F1F4308F1Q35602667-7AF5DC75-2E9A-4888-B37F-FE97E78CF0CEQ35869563-B4CB0B4A-0EF9-44FA-932B-58D84B6466DCQ35992569-99D86E9A-2911-4B63-9AAC-73B7B6C52998Q36303686-8308BE10-1CCE-4B3D-87AB-2526271FC6D8Q36308501-C74DCD12-35DA-4995-BAD3-2099B209856FQ36319986-F815C162-18EA-4269-96A3-0B8193395DF8Q36473630-5D0433A3-2B28-45AF-A366-6495FB4EF805Q36653022-5138D784-A632-409E-B72A-1A96A4D96435Q36686892-6EFA6B16-3943-417C-80B7-ED612E4CA165Q36815116-72B92D9F-CD28-4793-AEF7-B61418E91CBCQ37053006-AC729105-18EF-4876-9F71-07D383F8E687Q37097550-E997C003-C352-4D64-8677-483BC3509F1AQ37104386-30D554B7-EB1C-456A-B661-9CBAC5B45DB9Q37116172-A7A325D2-3676-4BF7-AEDF-24274CC8B31BQ37125012-14FB4190-27A6-4896-98BB-F7A3D58010F2Q37163787-F9E57B3A-248F-48F4-9072-D1FC9D6AE3BCQ37178150-5BBBEB6C-AB55-424F-B4AD-98DE6DA10F68Q37334738-4975BD19-9922-4A40-963A-C2E3C339B1E1Q37337695-513685EB-C6C8-4182-A3E2-96047BFD7882Q37381775-4C9B6E2C-F6BF-4725-9C8F-697372821A7AQ37408456-D3D8E525-2396-4082-B5E5-D5E1E6BEF8F1Q37426733-BA9FD03D-2A1D-4EFD-A4E3-4551877611DEQ37596760-C0F0FE71-7FCD-4F6C-8647-13D3942B3362Q37712068-E9508EFD-A8DA-4556-9DEB-FD60F91F78C0Q38076772-F3E76244-CBA4-4B82-8221-54A962089E81Q40077368-5A82F287-5687-4ADE-8474-48E85E6B01E3
P2860
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Determinants of androgen depri ...... cancer: role of the urologist.
@ast
Determinants of androgen depri ...... cancer: role of the urologist.
@en
type
label
Determinants of androgen depri ...... cancer: role of the urologist.
@ast
Determinants of androgen depri ...... cancer: role of the urologist.
@en
prefLabel
Determinants of androgen depri ...... cancer: role of the urologist.
@ast
Determinants of androgen depri ...... cancer: role of the urologist.
@en
P2093
P2860
P356
P1476
Determinants of androgen depri ...... cancer: role of the urologist.
@en
P2093
James S Goodwin
Jean L Freeman
Vahakn B Shahinian
Yong-Fang Kuo
P2860
P304
P356
10.1093/JNCI/DJJ230
P407
P577
2006-06-01T00:00:00Z